BioPorto A/S (THOXF)
USD 0.29
(0.0%)
USD 0.29
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -59.15 Million DKK | 16.86% |
| 2022 | -71.14 Million DKK | -118.99% |
| 2021 | -32.48 Million DKK | 66.6% |
| 2020 | -97.26 Million DKK | -574.88% |
| 2019 | -14.41 Million DKK | 69.05% |
| 2018 | -46.56 Million DKK | 0.7% |
| 2017 | -46.89 Million DKK | -31.82% |
| 2016 | -35.57 Million DKK | -2.29% |
| 2015 | -34.78 Million DKK | -37.25% |
| 2014 | -25.34 Million DKK | 40.62% |
| 2013 | -42.67 Million DKK | -975.11% |
| 2012 | 4.87 Million DKK | 236.34% |
| 2011 | 1.45 Million DKK | -31.86% |
| 2010 | 2.12 Million DKK | 119.25% |
| 2009 | -11.05 Million DKK | 14.36% |
| 2008 | -12.9 Million DKK | 53.06% |
| 2007 | -27.49 Million DKK | -39746.38% |
| 2006 | -69 Thousand DKK | 98.41% |
| 2005 | -4.33 Million DKK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -38.75 Million DKK | 34.48% |
| 2024 Q2 | -98.19 Million DKK | -153.37% |
| 2023 Q1 | -51.16 Million DKK | 28.08% |
| 2023 Q2 | -79.73 Million DKK | -55.84% |
| 2023 Q4 | -59.15 Million DKK | 9.07% |
| 2023 Q3 | -65.05 Million DKK | 18.42% |
| 2023 FY | -59.15 Million DKK | 16.86% |
| 2022 Q3 | -86.81 Million DKK | 9.11% |
| 2022 Q4 | -71.14 Million DKK | 18.04% |
| 2022 Q1 | -17.43 Million DKK | 46.34% |
| 2022 Q2 | -95.51 Million DKK | -447.89% |
| 2022 FY | -71.14 Million DKK | -118.99% |
| 2021 FY | -32.48 Million DKK | 66.6% |
| 2021 Q1 | -78.71 Million DKK | 19.07% |
| 2021 Q3 | -48.65 Million DKK | 27.64% |
| 2021 Q4 | -32.48 Million DKK | 33.22% |
| 2021 Q2 | -67.23 Million DKK | 14.59% |
| 2020 Q3 | -15.78 Million DKK | 23.86% |
| 2020 Q1 | -2.34 Million DKK | 83.74% |
| 2020 FY | -97.26 Million DKK | -574.88% |
| 2020 Q4 | -97.26 Million DKK | -516.06% |
| 2020 Q2 | -20.73 Million DKK | -784.6% |
| 2019 Q1 | -30.22 Million DKK | 35.1% |
| 2019 FY | -14.41 Million DKK | 69.05% |
| 2019 Q2 | -50.18 Million DKK | -66.06% |
| 2019 Q4 | -14.41 Million DKK | 57.02% |
| 2019 Q3 | -33.53 Million DKK | 33.18% |
| 2018 Q3 | -13.34 Million DKK | 40.76% |
| 2018 Q2 | -22.52 Million DKK | 33.25% |
| 2018 Q1 | -33.74 Million DKK | 28.25% |
| 2018 FY | -46.56 Million DKK | 0.7% |
| 2018 Q4 | -46.56 Million DKK | -248.93% |
| 2017 Q3 | -13.28 Million DKK | 33.93% |
| 2017 FY | -46.89 Million DKK | -31.82% |
| 2017 Q2 | -20.1 Million DKK | 31.11% |
| 2017 Q1 | -29.18 Million DKK | 17.98% |
| 2017 Q4 | -47.04 Million DKK | -254.19% |
| 2016 Q1 | -29.61 Million DKK | 14.85% |
| 2016 Q4 | -35.57 Million DKK | -87.79% |
| 2016 FY | -35.57 Million DKK | -2.29% |
| 2016 Q3 | -18.94 Million DKK | 21.08% |
| 2016 Q2 | -24 Million DKK | 18.95% |
| 2015 Q1 | -21.91 Million DKK | 13.51% |
| 2015 FY | -34.78 Million DKK | -37.25% |
| 2015 Q4 | -34.78 Million DKK | 15.34% |
| 2015 Q3 | -41.08 Million DKK | -129.52% |
| 2015 Q2 | -17.89 Million DKK | 18.34% |
| 2014 Q2 | -32.06 Million DKK | 10.96% |
| 2014 Q1 | -36.01 Million DKK | 15.62% |
| 2014 FY | -25.34 Million DKK | 40.62% |
| 2014 Q3 | -29.82 Million DKK | 6.98% |
| 2014 Q4 | -25.34 Million DKK | 15.03% |
| 2013 Q1 | 10.59 Million DKK | 117.14% |
| 2013 Q4 | -42.67 Million DKK | 6.71% |
| 2013 FY | -42.67 Million DKK | -975.11% |
| 2013 Q2 | 1.52 Million DKK | -85.57% |
| 2013 Q3 | -45.74 Million DKK | -3094.04% |
| 2012 FY | 4.87 Million DKK | 236.34% |
| 2012 Q2 | 9.89 Million DKK | 102.06% |
| 2012 Q4 | 4.87 Million DKK | -63.82% |
| 2012 Q1 | 4.89 Million DKK | 237.66% |
| 2012 Q3 | 13.47 Million DKK | 36.24% |
| 2011 Q2 | 7.7 Million DKK | 19.79% |
| 2011 Q4 | 1.45 Million DKK | 159.33% |
| 2011 Q3 | -2.44 Million DKK | -131.72% |
| 2011 Q1 | 6.43 Million DKK | 202.3% |
| 2011 FY | 1.45 Million DKK | -31.86% |
| 2010 Q4 | 2.12 Million DKK | 230.23% |
| 2010 Q1 | -7.77 Million DKK | 29.67% |
| 2010 FY | 2.12 Million DKK | 119.25% |
| 2010 Q3 | -1.63 Million DKK | 43.24% |
| 2010 Q2 | -2.87 Million DKK | 62.97% |
| 2009 Q4 | -11.05 Million DKK | 0.0% |
| 2009 FY | -11.05 Million DKK | 14.36% |
| 2008 FY | -12.9 Million DKK | 53.06% |
| 2007 FY | -27.49 Million DKK | -39746.38% |
| 2006 FY | -69 Thousand DKK | 98.41% |
| 2005 FY | -4.33 Million DKK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 2781.414% |
| Arrayit Corporation | 1.05 Million USD | 5703.744% |
| Atlantic International Corp. | 236.49 Thousand USD | 25111.84% |
| Biocept, Inc. | -788 Thousand USD | -7406.599% |
| Bioqual, Inc. | -12 Million USD | -392.642% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 260234.571% |
| DermTech, Inc. | 17.65 Million USD | 435.082% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 89.668% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | -701.853% |
| iMD Companies, Inc. | 1.11 Million USD | 5400.767% |
| IDenta Corp. | 524.85 Thousand USD | 11370.225% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 868.807% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -219371.653% |
| InVitro International | -313.14 Thousand USD | -18789.833% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 3877.474% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -8296113.184% |
| Medical Imaging Corp. | 3.79 Million USD | 1660.354% |
| NovelStem International Corp. | 3.52 Million USD | 1779.722% |
| Optigenex Inc. | 8.93 Million USD | 762.101% |
| PharmChem, Inc. | -1.49 Million USD | -3858.21% |
| Proteome Sciences plc | 14.57 Million USD | 505.893% |
| Response Genetics, Inc | -13.08 Million USD | -352.025% |
| Rennova Health, Inc. | 14.82 Million USD | 498.87% |
| RushNet, Inc. | 4.8 Million USD | 1332.116% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 43725.958% |
| Stella Diagnostics Inc. | 6.19 Million USD | 1055.134% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 3414.954% |
| Todos Medical Ltd. | 38.31 Million USD | 254.387% |